Novo Nordisk reports board and executive share transactions under EU market abuse rules
On August 6, 2026 Novo Nordisk issued a company announcement detailing share transactions made by members of its board, senior executives and their close associates in line with Article 19 of EU Regulation 596/2014 on market abuse.
The filing lists a transaction by board member Désirée Jantzen Asgreen involving the vesting of 74 restricted 100th Anniversary shares at a price of DKK 294.30 per share, amounting to a total value of DKK 21,778.20. The transaction occurred on August 5, 2026 and was executed outside a trading venue.
A similar disclosure was made for Elisabeth Dahl Christensen, also a board member, indicating another share vesting under the same restricted share programme. All reported transactions have been submitted to Novo Nordisk as required.
This writeup was produced by pharmadog from original reporting by globenewswire health.
Original headline: “Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons”
read at globenewswire health ↗
comments(0)
5-min edit window · permanent after that